Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...

Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...

Wolfe Research has upgraded Warner Bros. Discovery ( WBD, Financials) to "peer perform" from "underperform," citing a ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been and remains the treatment and prevention of HIV and liver ...

Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting catalysts in favor of Argenx – aside from myositis and ...

Wolfe Research upgrades Warner Bros. Discovery to peer perform, citing potential for stable EBITDA and debt reduction through ...

NEW YORK-- ( BUSINESS WIRE )--Hess Corporation (NYSE: HES) announced today that John Hess, Chief Executive Officer, will ...

Wolfe Research began coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research note published on Friday morning, MarketBeat.com reports. The firm issued an underperform rating and ...